SCHEMBL1508370

SCHEMBL1508370

OCc1cccc(-n2cccc2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VHL P40337 1/20 0.61
ELOC Q15369 1/20 0.61
ELOB Q15370 1/20 0.61
AOC2 O75106 2/20 0.56
CFTR P13569 1/20 0.51
MAPT P10636 1/20 0.50
ALOX5 P09917 1/20 0.44
ENPP2 Q13822 1/20 0.44
CYP11B1 P15538 1/20 0.42
CYP11B2 P19099 1/20 0.42
PRSS1 P07477 1/20 0.41
PRSS2 P07478 1/20 0.41
PRSS3 P35030 1/20 0.41
TSHR P16473 1/20 0.41
POLB P06746 2/20 0.40
NSD2 O96028 1/20 0.40
GRK2 P25098 1/20 0.40
CASP6 P55212 1/20 0.40
CTDSP1 Q9GZU7 1/20 0.40
MIF P14174 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9454096 0.93 VHL (0.53) VHLELOCELOBAOC2CFTR
SCHEMBL9454189 0.84 VHL (0.49) VHLELOCELOBAOC2CFTR
SCHEMBL9454562 0.84 VHL (0.49) VHLELOCELOBAOC2CFTR
SCHEMBL9454183 0.84 VHL (0.49) VHLELOCELOBAOC2CFTR
SCHEMBL9454859 0.84 VHL (0.45) VHLELOCELOBAOC2CFTR
SCHEMBL9454857 0.84 TSHR (0.52) VHLELOCELOBAOC2TSHR
SCHEMBL9454807 0.80 CFTR (0.49) VHLELOCELOBAOC2CFTR
SCHEMBL201853 0.79 AOC2 (0.51) VHLELOCELOBAOC2MAPT
SCHEMBL109402 0.79 AOC2 (0.56) VHLELOCELOBAOC2MAPT
SCHEMBL20780668 0.79 AOC2 (0.51) VHLELOCELOBAOC2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8222281-B2 Carboxylic acid compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-07-17 US disclosed
CN-102076650-A Carboxylic acid compound DAIICHI SANKYO CO LTD 2011-05-25 CN disclosed
US-20110053974-A1 CARBOXYLIC ACID COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-03-03 US disclosed
EP-2289868-A1 CARBOXYLIC ACID COMPOUND Daiichi Sankyo Company, Limited (JP) 2011-03-02 EP disclosed
US-20100048893-A1 Substituted arylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-02-25 US disclosed
US-20100048893-A1 Substituted arylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-02-25 US disclosed
US-20090062530-A1 Substituted arylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2009-03-05 US disclosed
US-20090062530-A1 Substituted arylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2009-03-05 US disclosed
US-7470807-B2 Suppress production of both prostaglandins and leukotrienes and have reduced side effects; treatment of various inflammatory diseases, autoimmune diseases, allergic diseases, pain and fibrosis; for example, methyl 3-[3-acetylamino-4-cyclopentyloxy-5-(naphthalen-2-yl)phenyl]propionate ASAHI KASEI PHARMA CORPORATION (JP) 2008-12-30 US disclosed
US-7470807-B2 Suppress production of both prostaglandins and leukotrienes and have reduced side effects; treatment of various inflammatory diseases, autoimmune diseases, allergic diseases, pain and fibrosis; for example, methyl 3-[3-acetylamino-4-cyclopentyloxy-5-(naphthalen-2-yl)phenyl]propionate ASAHI KASEI PHARMA CORPORATION (JP) 2008-12-30 US disclosed
US-20070213333-A1 Substituted arylalkanoic acid derivatives and use thereof ASAHI KASEI PHAMA CORPORATION (JP) 2007-09-13 US disclosed
US-5234946-A Anticholesterol, antilipemic BANYU PHARMACEUTICAL CO., LTD. (JP) 1993-08-10 US disclosed
EP-0318860-B1 SUBSTITUTED ALKYLAMINE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 1993-06-16 EP disclosed
EP-0395768-A1 SUBSTITUTED ALLYLAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE BANYU PHARMACEUTICAL CO., LTD. (JP) 1990-11-07 EP disclosed
CN-1042910-A The allylamine derivatives that replaces, their production method and application thereof BANYU PHARMA CO LTD (JP) 1990-06-13 CN disclosed
EP-0318860-A2 Substituted alkylamine derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 1989-06-07 EP disclosed
EP-0062659-A4 3-(PYRROL-1-YL)PHENYLMETHYL ESTERS AND INTERMEDIATES. FMC CORP (US) 1983-01-14 EP disclosed
EP-0062659-A1 3-(PYRROL-1-YL)PHENYLMETHYL ESTERS AND INTERMEDIATES FMC Corporation (US) 1982-10-20 EP disclosed
US-4339457-A OF CYCLOPROPANECARBOXYLIC ACIDS, INSECTICIDES, MITICIDES FMC CORPORATION (US) 1982-07-13 US disclosed
WO-1982001368-A1 3-(PYRROL-1-YL)PHENYLMETHYL ESTERS AND INTERMEDIATES FMC CORP (US) 1982-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053974-A1 CARBOXYLIC ACID COMPOUND AKR1C3, SLC5A1, GPR119 VHL 2193/4885ELOC 1255/4885ELOB 2331/4885
US-20100048893-A1 Substituted arylalkanoic acid derivatives and use thereof CYSLTR1, CYSLTR2, LTB4R2 VHL 2805/4885ELOC 2071/4885ELOB 2208/4885
US-20070213333-A1 Substituted arylalkanoic acid derivatives and use thereof CYSLTR1, CYSLTR2, LTB4R2 VHL 2805/4885ELOC 2071/4885ELOB 2208/4885
US-20090062530-A1 Substituted arylalkanoic acid derivatives and use thereof CYSLTR1, CYSLTR2, LTB4R2 VHL 2805/4885ELOC 2071/4885ELOB 2208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.